The research team, led by Xiaotian Huang, Jiaoyang Zheng, Yiwen Wang and Hao Chen of the Health Management Center at the Second Affiliated Hospital of Naval Medical University, confronted a methodological problem that has plagued earlier work in this field. Most previous studies comparing bone metabolism in diabetic patients with and without osteoporosis used comparison groups that could be contaminated by antiresorptive drugs. Patients labeled as having diabetes without osteoporosis may in fact have been receiving medications such as bisphosphonates or denosumab for other reasons, including bone metastases from cancer, and those drugs profoundly alter the very biomarkers researchers were trying to compare. The team therefore excluded anyone with bone metastasis and drew its comparison group exclusively from patients with no record of antiresorptive therapy.

The scale of the dataset gives the findings unusual weight. The researchers screened electronic health records of hospitalized patients with type 2 diabetes treated between 2021 and 2024, identifying 461 patients with a documented diagnosis of both diabetes and osteoporosis. From a pool of 21,181 patients with diabetes but no osteoporosis and no antiresorptive drug exposure, they selected a matched comparison group of 1,383 individuals using propensity score matching at a one-to-three ratio. Matching was performed on age and sex, which the authors describe as the two strongest confounders of bone metabolism given the data available. The procedure worked as intended: after matching, the standardized mean difference for both variables was exactly zero, with the combined cohort averaging 69.3 years of age and 15.2 percent male.

Against this carefully balanced backdrop, the team compared a panel of serum biomarkers that together sketch the state of bone remodeling and mineral metabolism. Parathyroid hormone, or PTH, stood out immediately. Patients with both diabetes and osteoporosis had a mean PTH concentration of 40.3 nanograms per liter, compared with 52.0 nanograms per liter in the matched diabetes-only group, a relative reduction of 22.6 percent that was highly statistically significant and carried a moderate effect size, with Cohen’s d of minus 0.434. Yet the authors are careful to frame this correctly: the median values in both groups fell within the laboratory reference range of 15 to 65 nanograms per liter, meaning the difference represents a shift within the normal spectrum rather than outright hormone deficiency.

The rest of the biomarker panel told a quieter story. Serum calcium was statistically higher in the osteoporosis group, at 2.21 versus 2.20 millimoles per liter, but the authors themselves flag that an absolute difference of one hundredth of a millimole per liter is unlikely to carry any clinical meaning. Bone turnover markers, the dynamic readouts of skeletal remodeling, showed no significant differences at all. Beta-C-terminal telopeptide of type I collagen, known as beta-CTX, a marker of bone resorption, was essentially identical between groups at 0.38 nanograms per milliliter. Osteocalcin, a marker of bone formation produced by osteoblasts, averaged 12.0 versus 11.0 nanograms per milliliter, a difference that did not reach statistical significance. Even 25-hydroxyvitamin D, the storage form of vitamin D that constrains PTH secretion, was statistically indistinguishable at 24.7 versus 22.8 nanograms per milliliter.

One secondary analysis added a layer of physiological nuance. In the diabetes-only group, glycated hemoglobin, or HbA1c, the standard measure of long-term blood sugar control, showed a moderate negative correlation with osteocalcin, with a correlation coefficient of minus 0.456. This relationship is well described in the literature: osteoblasts and the skeleton participate in energy metabolism, and poor glycemic control appears to suppress osteocalcin. In the combined diabetes and osteoporosis group, however, the correlation was much weaker, at minus 0.206, though still statistically significant. The attenuation suggests that in patients whose skeletons are already compromised by osteoporosis, the glucose-osteocalcin axis may be distorted or dominated by other forces, although a cross-sectional design cannot determine which way the causality runs.

What could explain suppressed PTH in patients whose bones are demonstrably weaker? The authors discuss two candidate mechanisms, both of which they emphasize remain unproven. The first involves altered sensitivity of the calcium-sensing receptor, or CaSR, the molecular thermostat on parathyroid cells that tunes hormone release according to circulating calcium. Advanced glycation end products, the sugar-damaged proteins that accumulate in diabetes, are one plausible influence on receptor behavior, and a shift in CaSR set-point could hold PTH lower even at normal calcium levels. The second is the concept of functional hypoparathyroidism, in which the glands are structurally intact but fail to mount an adequate hormonal response. Either mechanism would matter clinically, because PTH helps maintain bone remodeling balance, and an inappropriately low level could theoretically contribute to the skeletal fragility that defines diabetic bone disease.

The study’s limitations are candidly stated and worth understanding, because they define exactly what the finding does and does not prove. The entire population consisted of patients with type 2 diabetes, so the data cannot establish whether diabetes itself alters bone turnover relative to people without diabetes. Osteoporosis classification relied on diagnostic codes in the electronic health record rather than uniform dual-energy X-ray absorptiometry confirmation for every participant, and estimated glomerular filtration rate data were not incorporated into the analysis, even though declining kidney function is a well-known driver of elevated PTH and could confound the comparison. The design is cross-sectional, capturing a single moment in time, so it can document association but never causation. The authors call for future studies with confirmed bone mineral density measurements, renal function data, and longitudinal follow-up to test the CaSR and functional hypoparathyroidism hypotheses directly.

Why does this matter beyond the statistics? Diabetes doubles the burden of fracture in ways that bone mineral density scans often fail to capture, a phenomenon researchers call diabetic bone disease, in which the skeleton may look adequate on imaging but behaves as fragile tissue under stress. If suppressed PTH proves to be a genuine and mechanistically meaningful feature of this condition, it could eventually serve as a biomarker for identifying diabetic patients at heightened skeletal risk, or even suggest therapeutic angles, since PTH analogs such as teriparatide are already used to build bone in osteoporosis. The Shanghai team’s contribution is methodological as much as biological: by scrubbing antiresorptive drug confounders from the comparison group and matching rigorously on age and sex, they have produced one of the cleaner snapshots to date of bone metabolism in the diabetes-osteoporosis overlap, and the picture they captured, a 22.6 percent PTH reduction against an otherwise unremarkable panel, is a lead worth chasing.

For now, the practical takeaway for clinicians is one of calibrated caution. Both groups’ median PTH values sat comfortably within the normal range, bone turnover markers did not differ, and the calcium difference was trivially small, so no immediate change in screening or treatment practice follows from this single study. What the research does deliver is a sharpened hypothesis and a template for testing it. As the authors conclude, the mechanisms involving altered calcium-sensing receptor sensitivity or functional hypoparathyroidism remain unproven and require direct investigation. Given that hundreds of millions of people worldwide live with type 2 diabetes and that fragility fractures carry enormous costs in mortality and independence, even a modest hormonal clue about why diabetic bones fail deserves the longitudinal, density-confirmed follow-up studies the researchers now propose.

Subject of Research: Parathyroid hormone and calcium homeostasis in type 2 diabetes patients with osteoporosis

Article Title: Parathyroid hormone suppression and calcium homeostasis shift in type 2 diabetes with osteoporosis: a propensity score-matched cross-sectional study

Article References: Huang, X., Zheng, J., Wang, Y., & Chen, H. (2026). Parathyroid hormone suppression and calcium homeostasis shift in type 2 diabetes with osteoporosis: a propensity score-matched cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02549-8

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02549-8

Keywords: type 2 diabetes, osteoporosis, parathyroid hormone, bone turnover markers, calcium homeostasis, propensity score matching, cross-sectional study, vitamin D, osteocalcin, beta-CTX, calcium-sensing receptor, diabetic bone disease

The central characters of the study belong to the UPF0016 family, an evolutionarily ancient group of membrane proteins found across fungi, plants, algae, and animals. In budding yeast, the family member Gdt1 works alongside the P-type ATPase Pmr1, a calcium and manganese pump, to maintain ion levels in the Golgi lumen. In humans, the corresponding protein TMEM165 is so essential that mutations in its gene cause congenital disorders of glycosylation, a group of serious developmental conditions. Yet S. pombe is unusual: unlike most species examined so far, it carries two UPF0016 paralogs, Gdt1 and Gdt2, whose physiological roles had remained essentially unexplored.

To dissect those roles, the researchers constructed single-gene deletion mutants lacking gdt1, gdt2, or pmr1, as well as all three possible double mutants, using one-step gene replacement with antibiotic resistance markers. They then subjected the strains to a battery of stress tests, spotting serial dilutions of cells onto agar plates laced with calcium chloride at 300, 400, and 750 millimolar, or manganese chloride at 0.8, 1.5, and 2 millimolar. The pattern that emerged was striking. Cells lacking gdt1 were markedly hypersensitive to both cations, while deletion of gdt2 or pmr1 alone produced only mild growth defects under the tested conditions.

The double mutants told a more dramatic story. Combining gdt1 and gdt2 deletions produced the most severe calcium-sensitive phenotype, with virtually no growth at 750 millimolar CaCl2, evidence that the two paralogs partially substitute for one another. The gdt1 pmr1 double mutant displayed strong synthetic sickness, its growth nearly undetectable at 400 millimolar calcium even though each single mutant survived with moderate defects. The gdt2 pmr1 combination was weaker but still明显 impaired, with residual growth persisting even at the highest dose. Together these genetic interactions indicate that Gdt1, Gdt2, and Pmr1 operate in complementary, overlapping pathways rather than as a single linear chain.

A chelation experiment confirmed the mechanism behind the toxicity. When the calcium-specific chelator EGTA was added to plates containing 400 millimolar CaCl2, growth of both the gdt1 mutant and the gdt2 pmr1 double mutant was substantially restored. This rescue demonstrates that the growth failures stem specifically from an inability to cope with excess free extracellular calcium, not from a general fitness defect. Manganese assays echoed the calcium results: the gdt1 gdt2 double mutant was nearly unable to grow at 2 millimolar MnCl2, while the gdt2 pmr1 strain grew reasonably well even at that concentration, showing that Gdt1 alone can sustain manganese tolerance across the range tested.

Growth curves in liquid culture reinforced the hierarchy. Wild-type cells reached an optical density of about 13.2 after 32 hours, whereas the gdt1 mutant plateaued at only 5.3, the lowest of the single mutants, followed by gdt2 at 7.4 and pmr1 at 8.5. Every double mutant fared worse than any single mutant, with the gdt1 pmr1 combination most severely affected at an optical density near 3.1. The data identify Gdt1 as the primary growth determinant among the three proteins and reinforce the conclusion that its function cannot be fully replaced by its paralog or by the ATPase.

Microscopy added a visible dimension to the genetics. Under standard conditions, healthy fission yeast cells are elongated rods, but all mutant strains were significantly shorter and rounder, averaging around 7.0 to 7.2 micrometers in length compared with 11.7 micrometers for wild type. Stress amplified these defects in distinctive ways: high calcium drove abnormal elongation, with the gdt1 pmr1 double mutant stretching to an average of 15.7 micrometers, while manganese produced the most extreme swelling, widening mutant cells to as much as 8.2 micrometers, nearly double the wild-type diameter. These distortions are consistent with compromised cell wall biosynthesis and disrupted glycosylation, processes known to depend on luminal calcium and manganese in the secretory pathway.

The study also delved into structure. Multiple sequence alignments across UPF0016 homologs from budding yeast, Candida albicans, Arabidopsis, Chlamydomonas, and humans showed that the two fission yeast proteins share 48.44 percent amino acid identity and both retain the family’s signature motifs, EIGDKT and EWGDRS, whose conserved glutamate and aspartate residues had previously been shown to be essential for calcium transport. Topology predictions, however, revealed a divergence: SpGdt1 is predicted to span the membrane five times, while SpGdt2 carries six transmembrane helices. In silico modeling with the MIB2 server mapped candidate metal-binding residues, identifying Glu38 and Glu190 as likely manganese coordinators in Gdt1, supported by Asp41 and Ser43 for the larger calcium ion, and Glu61 and Glu214 in the corresponding positions of Gdt2.

Phylogenetic analysis placed the fission yeast proteins on their own branch, separate from the single homolog of budding yeast, suggesting that the gdt1 and gdt2 pair arose from a lineage-specific gene duplication after the two yeast lineages split. Localization predictions using DeepLoc 2.0, together with curated PomBase and ORFeome annotations, assign SpGdt1 primarily to the endoplasmic reticulum and SpGdt2 to both the ER and Golgi, a compartmental pattern that differs from the Golgi residency of the budding yeast protein and may explain why the fission yeast pump Pmr1 itself localizes mainly to ER membranes in earlier fluorescence studies.

The implications reach well beyond a single yeast species. Because glycosylation enzymes require manganese and calcium cofactors, defects in UPF0016-dependent ion regulation can cascade into failures of protein maturation, secretion, and cell wall construction, which is precisely why human TMEM165 mutations manifest as congenital glycosylation disorders and why plant homologs such as PAM71 are indispensable for chloroplast manganese uptake and efficient photosynthesis. By establishing that Gdt1 is the dominant determinant of divalent cation tolerance in fission yeast while Gdt2 and Pmr1 provide complementary support, the study completes a missing evolutionary link and sets the stage for direct transport assays, motif-directed mutants, and organelle-level imaging to confirm how these conserved transporters move metal ions across secretory pathway membranes.

Subject of Research: Regulation of calcium and manganese ion homeostasis by UPF0016 family proteins Gdt1, Gdt2 and the P-type ATPase Pmr1 in the fission yeast Schizosaccharomyces pombe

Article Title: Gdt1, Gdt2 and the P-type ATPase Pmr1 regulate divalent cations (Ca²⁺ and Mn²⁺) in the fission yeast Schizosaccharomyces pombe

Article References: Ullah, F., & Huang, Y. (2026). Gdt1, Gdt2 and the P-type ATPase Pmr1 regulate divalent cations (Ca²⁺ and Mn²⁺) in the fission yeast Schizosaccharomyces pombe. International Microbiology. https://doi.org/10.1007/s10123-026-00887-0

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00887-0

Keywords: Schizosaccharomyces pombe, UPF0016 family, Gdt1, Gdt2, Pmr1, calcium homeostasis, manganese transport, Golgi apparatus, endoplasmic reticulum, protein glycosylation, cell wall integrity, TMEM165